| | |
| Clinical data | |
|---|---|
| Other names | LR 1111 |
| Identifiers | |
| |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C29H36N2O |
| Molar mass | 428.620 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
LR-1111 is an analog of GBR-12935 that was discovered by Richard Rothman and co-workers in the 1990's. It differs from GBR-12935 in that the piperazine has been expanded to a homopiperazine (azepane) ring. [1] LR-1111 is a dopamine reuptake inhibitor (DRI) with over 4000 times selectivity for the dopamine transporter (DAT) relative to the serotonin transporter (SERT) and the norepinephrine transporter (NET). [2] [3]